2018 SHBC Lightning Talks


Lightning talk #1 - Discover

 
image4.jpg

Aditya Khosla, Co-founder and CTO of PathAI


Aditya is the co-founder and CTO of PathAI, a venture backed company focused on improving cancer diagnosis and treatment through the use of artificial intelligence. He recently completed his PhD in machine learning and computer vision at MIT. He completed his MS at Stanford in 2011 and BS at Caltech in 2009. In his research he developed new methods for an array of applications in computer vision, including eye-tracking, prediction of image memorability, and visualization of deep networks. He is the recipient of a Facebook Fellowship and his work has been widely covered by various media outlets including BBC, The New York Times and The Washington Post. He has published over 30 papers in the fields of deep learning, computer vision and neuroscience


Lightning talk #2 - PARTNER

Michal Preminger, Ph.D., M.B.A | 

 
Picture1.png

Executive Director, Harvard University Office of Technology Development, Harvard Medical School

Dr. Preminger is Executive Director at Harvard’s Office of Technology Development at Harvard Medical School, where she oversees industry partnerships and startup formation. Prior to joining Harvard in 2005, she held a number of senior executive BD and R&D positions in tech and biotechnology companies. In addition, she is currently a member of the Board of Directors at BioArray Genetics and Compugen, and a member of the SAB at Futurx (Takeda/J&J/Orbimed Partnership) and Prize4Life. Dr. Preminger holds a PhD from the Weizmann Institute of Science, and an MBA from INSEAD, France.


LIGHTNING TALK #3 - SCALE and IMPACT

GAURAV SINGAL | VP, Data Strategy & Product at Foundation Medicine

 
Gaurav+pic.jpg

Gaurav Singal, M.D., is a physician and computer scientist who leads Data Strategy and Product Development at Foundation Medicine, a molecular information company leading the incorporation of precision medicine into oncology care.

In this role, Dr. Singal and his team have been responsible for the design, development, and launch of numerous software platforms that support molecular oncology research and clinical practice, including Foundation Medicine’s decision support platform, the Interactive Cancer Explorer® (FoundationICE), and its data analytics platform, FoundationICE Insights. Additionally, Dr. Singal and his team are responsible for enabling use of real world data linked with genomic data for research and development, and for
developing the SmartTrials program, a suite of products and services helping cancer patients with rare genomic findings receive novel targeted therapies through clinical trials.

Prior to joining Foundation Medicine, Dr. Singal developed several natural language processing (NLP)-based applications to improve care delivery and research at Massachusetts General Hospital, as well as a number of award-winning international websites. Dr. Singal earned a B.S., Summa Cum Laude, in computer engineering from Columbia University and an M.D. with Honors from the joint Harvard Medical School-MIT Division of Health Sciences and Technology. He continues to practice medicine as an
attending physician at Brigham and Women’s Hospital, is on faculty at Harvard Medical School, where he co-directs a course on health technology and innovation.


LIGHTNING TALK #4 - FUTURE

Luis Alvarez | Director, Organ Manufacturing at United Therapeutics

pic.png

Luis Alvarez is the Director of Organ Manufacturing at United Therapeutics (NASDAQ: UTHR). The Organ Manufacturing Group is a moonshot project developing a novel bioprinting platform to manufacture transplantable human lungs. Previously Luis was the founding Deputy Director of the Department of Defense Regenerative Medicine Program Office where he oversaw preclinical and clinical development programs. He also served as the Director of the DoD's $720M nerve agent pharmaceutical countermeasures program. In 2014 Luis founded Theradaptive, an MIT spin-out and late-stage preclinical firm developing a biologics delivery platform for orthopedic regeneration. In 2017 he co-founded Elevian, a Harvard spinout that is developing therapeutics to treat aging-associated diseases. Luis is a graduate of West Point and served 20 years on active duty with US Army. He is a decorated combat veteran and is a recipient of the Combat Action Badge and Bronze Star Medal. He holds a PhD in Biological Engineering and an MS in Chemical Engineering from MIT where he was a Hertz Foundation Fellow.